Hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib as frontline therapy for Ph-positive ALL: a propensity score analysis

Documenti analoghi

• First Report of a Phase II Prospective Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  di: Jabbour, Elias, et al.
  Pubblicazione: (2015)
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab vs. Standard Intensive Chemotherapy (hyper-CVAD) as Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: a Propensity Score Analysis
  di: Jabbour, Elias, et al.
  Pubblicazione: (2019)
• Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
  di: Daver, Naval, et al.
  Pubblicazione: (2015)
• Frontline treatment of acute myeloid leukemia in adults
  di: Tamamyan, Gevorg, et al.
  Pubblicazione: (2016)
• A Propensity Score Matching Analysis of Dasatinib and Nilotonib as a Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase
  di: Takahashi, Koichi, et al.
  Pubblicazione: (2016)